PHR250117P17500
- 0.14
- 0.000.00%
Phreesia Newsroom
Citigroup Maintains Buy on Phreesia, Raises Price Target to $35
Needham Maintains Phreesia(PHR.US) With Buy Rating, Maintains Target Price $29
Needham Reiterates Buy on Phreesia, Maintains $29 Price Target
Phreesia's Growth Potential and Balanced Strategy Justifies Buy Rating
Phreesia Insider Sold Shares Worth $274,051, According to a Recent SEC Filing
Phreesia Is Maintained at Overweight by Keybanc
Here's Why Phreesia's Average Revenue Per Client Will Accelerate: Analyst
Should You Buy Phreesia (PHR) After Golden Cross?
Possible Bearish Signals With Phreesia Insiders Disposing Stock
Phreesia Analyst Ratings
KeyBanc Maintains Phreesia(PHR.US) With Buy Rating, Raises Target Price to $30
RBC Capital Upgrades Phreesia(PHR.US) to Buy Rating, Raises Target Price to $32
Express News | Phreesia Inc : RBC Raises to Outperform From Sector Perform; Raises Target Price to $32 From $24
D.A. Davidson Maintains Phreesia(PHR.US) With Buy Rating, Announces Target Price $36
Wall Street Analysts See a 25% Upside in Phreesia (PHR): Can the Stock Really Move This High?
Phreesia (PHR) Receives a Buy From J.P. Morgan
There's Reason For Concern Over Phreesia, Inc.'s (NYSE:PHR) Massive 38% Price Jump
Phreesia Insider Sold Shares Worth $294,559, According to a Recent SEC Filing
Analysts Offer Insights on Healthcare Companies: Pharming Group (OtherPHGUF) and Phreesia (PHR)
RBC Capital Sticks to Its Hold Rating for Phreesia (PHR)